Publications by authors named "Jasmin Emmenegger"
Article Synopsis
- The existing BRAF and MEK inhibitors used for treating BRAF V600E/K-mutated melanoma have limited and short-lived effectiveness, particularly in brain metastases, leading to a need for better treatments.
- Researchers introduced a new potent BRAF inhibitor (C1a) that works well as a first-line therapy and after patients have relapsed from standard treatments, showing superior results in lab and animal models.
- The study found that C1a remains effective despite some resistance mechanisms, identifying potential genetic causes of treatment failure and suggesting that combining C1a with anti-PD-1 therapy could further enhance treatment outcomes.
Purpose: Disease progression in BRAF V600E/K positive melanomas to approved BRAF/MEK inhibitor therapies is associated with the development of resistance mediated by RAF dimer inducing mechanisms. Moreover, progressing disease after BRAFi/MEKi frequently involves brain metastasis. Here we present the development of a novel BRAF inhibitor (Compound Ia) designed to address the limitations of available BRAFi/MEKi.
View Article and Find Full Text PDF